治疗前定量影像与剂量测定在晚期甲状腺癌放射性碘治疗中的作用
一项多中心临床试验探讨司美替尼调节钠碘同向转运体表达以影响碘摄取,在放射性碘难治性分化型甲状腺癌治疗中的作用。治疗前后定量碘摄取并计算转移灶吸收剂量,发现吸收剂量范围从小于1 Gy至1,170 Gy,治疗前影像预测剂量与治疗后实测剂量呈强正相关(r=0.93,P<0.001)。
要点
- 司美替尼对放射性碘摄取的影响及碘摄取本身在患者间和患者内均存在显著变异。
- 转移灶吸收剂量范围为小于1 Gy至1,170 Gy。
- 治疗前影像预测的吸收剂量与治疗后实测值强正相关(r=0.93,P<0.001)。
核心结论
- 放射性碘治疗分化型甲状腺癌的结局差异可能部分由所递送吸收剂量的范围来解释。
- 评估调节放射性碘摄取的药物效果并估算治疗时吸收剂量的能力,引入了采用诊疗一体化方法进行患者分层的潜力。
- 患者个体化吸收剂量规划可能是更成功治疗晚期分化型甲状腺癌的关键。
研究设计与样本
- 多中心临床试验,研究司美替尼(调节钠碘同向转运体表达从而影响碘摄取)在放射性碘难治性分化型甲状腺癌治疗中的作用。
- 定量测定司美替尼治疗前后的碘摄取以评估其效果,并根据治疗前和治疗后影像计算转移灶吸收剂量范围,探讨诊疗一体化方法实现个体化治疗规划的预测准确性。
主要发现
- 在放射性碘摄取和司美替尼效果方面观察到显著的 patient 间和患者内变异。
- 转移灶吸收剂量范围为小于1 Gy至1,170 Gy。
- 治疗前影像预测的吸收剂量与治疗后实测吸收剂量之间呈强正相关(r=0.93,P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radioactive iodine is well established as a successful treatment for differentiated thyroid cancer (DTC), although around 15% of patients have local recurrence or develop distant metastases and may become refractory to radioactive iodine (RAI). A personalized approach to treatment, based on the absorbed radiation doses delivered and using treatments to enhance RAI uptake, has not yet been developed. Methods: We performed a multicenter clinical trial to investigate the role of selumetinib, which modulates the expression of the sodium iodide symporter, and hence iodine uptake, in the treatment of RAI-refractory DTC. The iodine uptake before and after selumetinib was quantified to assess the effect of selumetinib. The range of absorbed doses delivered to metastatic disease was calculated from pre- and posttherapy imaging, and the predictive accuracy of a theranostic approach to enable personalized treatment planning was investigated. Results: Significant inter- and intrapatient variability was observed with respect to the uptake of RAI and the effect of selumetinib. The absorbed doses delivered to metastatic lesions ranged from less than 1 Gy to 1,170 Gy. A strong positive correlation was found between the absorbed doses predicted from pretherapy imaging and those measured after therapy (r = 0.93, P < 0.001). Conclusion: The variation in outcomes from RAI therapy of DTC may be explained, among other factors, by the range of absorbed doses delivered. The ability to assess the effect of treatments that modulate RAI uptake, and to estimate the absorbed doses at therapy, introduces the potential for patient stratification using a theranostic approach. Patient-specific absorbed dose planning might be the key to more successful treatment of advanced DTC.
引用
- Taprogge J, Abreu C, Yusuf S, et al. The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer. J Nucl Med. 2023. PMID: 37116914. doi:10.2967/jnumed.122.264913
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。